Patents Assigned to TRT Innovations APS
  • 177-Lu labeled peptide for site-specific uPAR-targeting
    Patent number: 12589171
    Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: March 31, 2026
    Assignee: TRT INNOVATIONS APS
    Inventors: Andreas Kjaer, Morten Persson, Michael Ploug
  • 177-Lu labeled peptide for site-specific uPAR-targeting
    Patent number: 10994032
    Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: May 4, 2021
    Assignee: TRT Innovations APS
    Inventors: Andreas Kjaer, Morten Persson, Michael Ploug